Fingolimod for relapsing multiple sclerosis: an update

Bibliography

• Pugliatti M, Rosati G, Carton H, The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
   PubMed Web of Science ®Google Scholar
• Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005;19:239-52
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9
   PubMed Web of Science ®Google Scholar
• Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008;75:1893-900
   PubMed Web of Science ®Google Scholar
• Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307
   PubMed Web of Science ®Google Scholar
• Salvadori M, Budde K, Charpentier B, FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6:2912-21
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Pescovitz MD, Cibrik D, Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82:1689-97
   PubMed Web of Science ®Google Scholar
• Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother 2008;8:699-714
   PubMedGoogle Scholar
• Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 2004;92:882-99
   PubMed Web of Science ®Google Scholar
• Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-22
   PubMed Web of Science ®Google Scholar
• Jaillard C, Harrison S, Stankoff B, Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005;25:1459-69
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005;5:560-70
   PubMed Web of Science ®Google Scholar
• Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105
   PubMed Web of Science ®Google Scholar
• McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004;92:1075-85
   PubMed Web of Science ®Google Scholar
• Peters SL, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 2007;7:186-92
   PubMed Web of Science ®Google Scholar
• Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-301
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-7
   PubMed Web of Science ®Google Scholar
• Liu CH, Thangada S, Lee MJ, Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell 1999;10:1179-90
   PubMed Web of Science ®Google Scholar
• Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. Faseb J 2004;18:551-3
   PubMed Web of Science ®Google Scholar
• Oo ML, Thangada S, Wu MT, Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007;282:9082-9
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Zecri F, Cetin C, Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009;5:428-34
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
   PubMed Web of Science ®Google Scholar
• Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004;279:15396-401
   PubMed Web of Science ®Google Scholar
• Schwab SR, Pereira JP, Matloubian M, Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309:1735-9
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-34
   PubMed Web of Science ®Google Scholar
• Pappu R, Schwab SR, Cornelissen I, Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-8
   PubMed Web of Science ®Google Scholar
• Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 2005;201:291-301
   PubMed Web of Science ®Google Scholar
• Chiba K, Yanagawa Y, Masubuchi Y, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-44
   PubMed Web of Science ®Google Scholar
• Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology 1998;95:591-4
   PubMed Web of Science ®Google Scholar
• Yanagawa Y, Sugahara K, Kataoka H, FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998;160:5493-9
   PubMed Web of Science ®Google Scholar
• Hwang MW, Matsumori A, Furukawa Y, FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999;100:1322-9
   PubMed Web of Science ®Google Scholar
• Kurose S, Ikeda E, Tokiwa M, Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res 2000;70:7-15
   PubMed Web of Science ®Google Scholar
• Fujino M, Funeshima N, Kitazawa Y, Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-7
   PubMed Web of Science ®Google Scholar
• Kataoka H, Sugahara K, Shimano K, FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005;2:439-48
   PubMed Web of Science ®Google Scholar
• Xie JH, Nomura N, Koprak SL, Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol 2003;170:3662-70
   PubMed Web of Science ®Google Scholar
• Drennan MB, Elewaut D, Hogquist KA. Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond. Eur J Immunol 2009;39:925-30
   PubMed Web of Science ®Google Scholar
• Lan YY, De Creus A, Colvin BL, The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005;5:2649-59
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-7
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000;21:49-52
   PubMed Web of Science ®Google Scholar
• Pinschewer DD, Ochsenbein AF, Odermatt B, FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761-70
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-25
   PubMed Web of Science ®Google Scholar
• McFarland HF. The B cell-old player, new position on the team. N Engl J Med 2008;358:664-5
   PubMed Web of Science ®Google Scholar
• Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-25
   PubMed Web of Science ®Google Scholar
• Dev KK, Mullershausen F, Mattes H, Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117:77-93
   PubMed Web of Science ®Google Scholar
• Pebay A, Toutant M, Premont J, Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 2001;13:2067-76
   Web of Science ®Google Scholar
• Mullershausen F, Craveiro LM, Shin Y, Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007;102:1151-61
   PubMed Web of Science ®Google Scholar
• Miron VE, Jung CG, Kim HJ, FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
   PubMed Web of Science ®Google Scholar
• MacLennan AJ, Devlin BK, Marks L, Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth. Dev Neurosci 2000;22:283-95
   PubMed Web of Science ®Google Scholar
• Sorensen SD, Nicole O, Peavy RD, Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64:1199-209
   PubMed Web of Science ®Google Scholar
• Yamagata K, Tagami M, Torii Y, Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003;41:199-206
   PubMed Web of Science ®Google Scholar
• Toman RE, Payne SG, Watterson KR, Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166:381-92
   PubMed Web of Science ®Google Scholar
• Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004;88:1026-39
   PubMed Web of Science ®Google Scholar
• Saini HS, Coelho RP, Goparaju SK, Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J Neurochem 2005;95:1298-310
   PubMed Web of Science ®Google Scholar
• Rouach N, Pebay A, Meme W, S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur J Neurosci 2006;23:1453-64
   PubMed Web of Science ®Google Scholar
• Novgorodov AS, El-Alwani M, Bielawski J, Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. Faseb J 2007;21:1503-14
   PubMed Web of Science ®Google Scholar
• Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274:13-7
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323:469-75
   PubMed Web of Science ®Google Scholar
• Coelho RP, Payne SG, Bittman R, The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323:626-35
   PubMed Web of Science ®Google Scholar
• Miron VE, Hall JA, Kennedy TE, Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 2008;173:1143-52
   PubMed Web of Science ®Google Scholar
• Jung CG, Kim HJ, Miron VE, Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007;55:1656-67
   PubMed Web of Science ®Google Scholar
• Deogracias R, Klein C, Matsumoto T, Expression of brain-derived neurotrophic factor is regulated by fingolimod (FTY720) in cultured neurons. Multiple Sclerosis 2008;14:S243 [P728]
   PubMedGoogle Scholar
• Choi JW, Herr D, Lee CW, S1P1 receptor signaling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and the efficacy of fingolimod (FTY720). Multiple Sclerosis 2008;14:S37 [P29]
   Web of Science ®Google Scholar
• Choi JW, Herr D, Kennedy G, Chun J. Astrocytic sphingosine-1-phosphate (S1P) receptor subtype 1 signalling influences levels of S1P and cytokines during experimental autoimmune encephalomyelitis and fingolimod (FTY720) intervention. Multiple Sclerosis 2009;15:S58 [P227]
   Google Scholar
• Budde K, Schmouder RL, Brunkhorst R, First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13:1073-83
   PubMed Web of Science ®Google Scholar
• Budde K, Schmouder RL, Nashan B, Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 2003;3:846-54
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder R, Barilla D, Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004;57:586-91
   PubMed Web of Science ®Google Scholar
• Kahan BD, Karlix JL, Ferguson RM, Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003;76:1079-84
   PubMed Web of Science ®Google Scholar
• Skerjanec A, Tedesco H, Neumayer HH, FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol 2005;45:1268-78
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder R, Barilla D, Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
   PubMed Web of Science ®Google Scholar
• O'Connor P, Comi G, Montalban X, Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9
   PubMed Web of Science ®Google Scholar
• Comi G, O'Connor P, Montalban X, Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Mazurais D, Robert P, Gout B, Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002;50:661-70
   PubMed Web of Science ®Google Scholar
• Gergely P, Wallström E, Nuesslein-Hildesheim B, Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Multiple Sclerosis 2009;15:S125 [P437]
   Google Scholar
• Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-36
   PubMed Web of Science ®Google Scholar
• Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 2002;91:151-7
   PubMed Web of Science ®Google Scholar
• Tolle M, Levkau B, Keul P, Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 2005;96:913-20
   PubMed Web of Science ®Google Scholar
• Pfaff M, Powaga N, Akinci S, Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir Res 2005;6:48
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Bartlett M, Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 2007;28:97-104
   PubMed Web of Science ®Google Scholar
• Paugh SW, Payne SG, Barbour SE, The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003;554:189-93
   PubMed Web of Science ®Google Scholar
• Kharel Y, Lee S, Snyder AH, Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005;280:36865-72
   PubMed Web of Science ®Google Scholar
• Zemann B, Kinzel B, Muller M, Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006;107:1454-8
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004;26:585-7
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder RL, Hartmann S, Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 2006;46:149-56
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder RL, Serra D, FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 2005;45:446-52
   PubMed Web of Science ®Google Scholar
• Clemens JJ, Davis MD, Lynch KR, Macdonald TL. Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. Bioorg Med. Chem Lett 2003;13:3401-4
   Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 2006;34:1480-7
   PubMed Web of Science ®Google Scholar
• Billich A, Bornancin F, Devay P, Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003;278:47408-15
   PubMed Web of Science ®Google Scholar
• Park SI, Felipe CR, Machado PG, Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. Braz J Med Biol Res 2005;38:683-94
   PubMed Web of Science ®Google Scholar
• Zimmerlin AG, Patten CJ. Role of CYP4F in the metabolic clearance of FTY720: prediction of low drug to drug interaction potential. Transplantation 2000;69:S191
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Dole K, Riviere GJ, Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009;49:212-8
   PubMed Web of Science ®Google Scholar
• Kahan BD. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther Drug Monit 2002;24:47-52
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hsu CH, Skerjanec A, FTY720 disposition is not affected by demographic or clinical factors in de novo kidney transplant patients. Am J Transplant 2003;5:S332[705]
   Google Scholar
• Kovarik JM, Slade A, Voss B, Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther 2007;45:98-109
   PubMed Web of Science ®Google Scholar
• Sensken SC, Bode C, Graler MH. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol Exp Ther 2009;328:963-9
   PubMed Web of Science ®Google Scholar
• Rausch M, Hiestand P, Foster CA, Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:16-24
   PubMed Web of Science ®Google Scholar
• Balatoni B, Storch MK, Swoboda EM, FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007;74:307-16
   PubMed Web of Science ®Google Scholar
• Foster CA, Mechtcheriakova D, Storch MK, FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009;19:254-66
   PubMed Web of Science ®Google Scholar
• Papadopoulos D, Rundle J, Patel R, FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J Neurosci Res 2010;88:346-59
   Google Scholar
• Webb M, Tham CS, Lin FF, Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153:108-21
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Mourad G, Kahan BD, FTY720, a novel immunomodulator: efficacy and safety results from the first phase IIA study in de novo renal transplantation. Transplantation 2005;79:1553-60
   PubMed Web of Science ®Google Scholar
• Schmouder R, Serra D, Wang Y, FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006;46:895-904
   PubMed Web of Science ®Google Scholar
• Mulgaonkar S, Tedesco H, Oppenheimer F, FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant 2006;6:1848-57
   PubMed Web of Science ®Google Scholar
• Oppenheimer F, Mulgaonkar S, Ferguson R, Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Transplantation 2007;83:645-8
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Slade A, Riviere GJ, The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol 2008;66:199-206
   PubMed Web of Science ®Google Scholar
• Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005;35:83-90
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Munchau A, Moeller F, Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009;72:1022-4
   PubMed Web of Science ®Google Scholar